CD274 and neoplasm: PD-L1 expression has also been demonstrated as an available predictor for the efficacy of anti-PD-1 monoclonal antibodies for other tumor types, and patients with low PD-L1 expression have limited efficacy from anti-PD-1 monoclonal antibodies (12).